Compare Globus Medical Inc. Class A Common Stock (GMED) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Nvidia Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Nvidia Corp trades at $217.53 (market cap $5.52T). The key difference: Nvidia Corp is far larger — about 538.5× Globus Medical Inc. Class A Common Stock's market cap, and Nvidia Corp pays a 0.44% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Nvidia Corp for 116 Days on average.
| GMED | NVDA | |
|---|---|---|
Market Cap | $10.25B | $5.52T |
Volume | 1,108,124 | 84,036,941 |
Sector | Health | Technology |
52-Week High | $96.82 | $239.27 |
52-Week Low | $58.33 | $165.17 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $9.76B | $5.49T |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
NVIDIA (NVDA) trades at $228.52, up 0.97% with strong fundamental performance including 55.84% net profit margin and consistent earnings beats. The stock shows bullish technical signals with support at $225 and resistance at $228. Revenue growth accelerated to $130.5B in 2025, while analyst consensus remains strongly bullish with a $339.17 price target representing 48% upside potential.
NVIDIA's AI leadership and expanding market position support continued growth, though valuation multiples remain elevated. Key risks include increased competition and potential market saturation in AI chips. The company's strong cash flow generation and institutional support provide fundamental backing for long-term investors despite near-term volatility concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
